摘要
目的探讨非小细胞肺癌组织核苷酸还原酶M1亚基(RRM1)蛋白表达水平与吉西他滨体外药敏的关系。方法用ATP生物荧光法(ATP-TCA)对44例非小细胞肺癌患者手术切除的新鲜标本进行吉西他滨体外药敏检测,并用免疫组织化学检测其RRM1蛋白表达水平,比较分析RRM1表达与吉西他滨耐药的相关性。结果RRM1高表达20例(45.5%),低表达24例(54.5%);结合吉西他滨体外药敏结果得出,RRM1蛋白低表达组吉西他滨有效为17例(70.8%);RRM1蛋白高表达组有效6例(30.0%),即RRM1蛋白低表达组对吉西他滨的体外疗效明显优于高表达组,(P<0.05)。结论RRM1蛋白表达水平可用于以吉西他滨为化疗基础的非小细胞肺癌患者的疗效预测指标。
Objective To determine the relationship between RRM1 protein expression and sensitivity of non-small-cell lung cancer to gemcitabine in vitro.Methods Tested the sensitivity of 44 operative fresh non-small-eell lung cancer tissues to gemeitabine with the method of ATP-TCA;The levels of RRM1 was detected by means of immunohistochemistry ,and then analyze the relation between the expression of RRM1 and chemosensitivity of gemcitibine.Results There were 20（45.5%）cases with the high levels of RRM1 protein group, and still another 24（54.5%） cases with the low levels of RRM1 protein group.On the basis of ATP-TCA assay,we can learned that there were 17 （70.8%）cases with sensitive to gemcitabine in the high levels of RRM1 protein group,and 6（30.0%） sensitive cases in the low levels of RRM1 protein group, A benefit from gemcitabine chemotherapy was associated with the absence of RRM1 （P〈0.05）.Conclusion RRMI may be an useful prognostic marker in patients with non-small-cell lung cancer treated with gemcitabine-based chemotherapeutic effect.
出处
《江西医药》
CAS
2009年第11期1074-1077,共4页
Jiangxi Medical Journal
关键词
非小细胞肺癌
RRM1
吉西他滨
ATP—TCA
免疫组织化学
耐药
non-small-cell lung carncer
ribonucleotide reductase subunit M 1
gemcitabine
ATP biolummescence
immunohis-tochemistry
drug resistance
